by Peter Ciszewski | May 11, 2017
The SIERRA Trial – Discussion – Video Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals discusses the SIERRA (Study of Iomab-B in Elderly Relapsed or Refractoy AML) trial, a multi-center, randomized, controlled pivotal Phase 3 study of Iomab-B...
by Peter Ciszewski | May 11, 2017
Discussion of Treatment Options for Acute Myelogenous Leukemia (AML) Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals discusses treatment options for acute myelogenous leukemia (AML), which comprise a variety of chemotherapy regimens and stem cell...
by Peter Ciszewski | May 11, 2017
Discussion of Medicines available to treat Rare Diseases – Video The European Medicines Agency plays a central role in the development and authorisation of medicines for rare diseases. These medicines are termed ‘orphan medicines’ in the medical...
by Peter Ciszewski | May 11, 2017
Discussion of Orphan Drug Costs – Video Last week, Nick Bagley argued that the benefits of the Orphan Drug Act are more elusive than commonly assumed. Nick Bagley, a professor of law at the University of Michigan discusses the costs of orphan drugs in this...
by Peter Ciszewski | May 11, 2017
Discussion of Issues concerning Orphan Drugs – Video In the United States, the median price for an orphan drug is about $100,000 per year, twenty times the price of the median non-orphan drug. Given the staggering cost, you’d think we’d have a solid...
